Skip to content

Adjunctive DobutAmine in sePtic cardiomyopathy with Tissue hypoperfusion: a randomized controlled multi-center trial

Status
Completed
Phases
Phase 3Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-517839-50-00
Acronym
87RI18_0012
Enrollment
136
Registered
2024-10-10
Start date
2020-09-20
Completion date
2025-07-01
Last updated
2025-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Brief summary

Evolution of a modified Sequential (Sepsis-Related) Organ Failure Assessment (SOFA) score (no gradation of the neurologic system) between baseline (before randomization) and Day 1, Day 2 and Day 3 after randomization.

Detailed description

Biological indices of tissue dysoxia at baseline, 6 h after initiating Dobutamine / placebo, Day 1, Day2, Day3: * Circulating lactate level as a marker of tissue hypoperfusion * Central venous oxygen saturation (ScvO2) as a marker of tissue oxygen extraction, Requirement of organ function supports during ICU stay: * Maximal dose and duration of open-labelled Dobutamine used as rescue therapy * Maximal dose and duration of vasopressor support (Norepinephrine, other) * Duration of invasive mechanical ventilation * Requirement and number of sessions of renal replacement therapy (excluding hemodialysis patient for chronic renal failure at the time of randomization, Hemodynamic status at baseline, 6 h after initiating Dobutamine / placebo, Day 1, Day2, Day3: * Arterial pressure, heart rate *Central venous pressure * Cardiac index and stroke volume measured using echocardiography or using calibrated monitoring systems (e.g., transpulmonary thermodilution), Severe cardiovascular adverse events during ICU stay: * Hypotension related to worsened vasoplegia * Excessive sinus tachycardia > 160 bpm * Supraventricular arrhythmias with ventricular rate > 140 bpm * Ventricular arrhythmias * New-onset acute coronary syndrome * Stroke (ischemic or hemorrhagic), Day-7, ICU, Day-28 and Day-90 all-cause mortality, Number of days free from vasopressor support, invasive mechanical ventilation, renal replacement therapy during ICU stay, Length of ICU and hospital stay, Echocardiography at baseline and on Day 1: LV ejection fraction using the monoplane Simpson method, velocity-time integral of LV outflow tract Doppler (stroke volume), E and A mitral Doppler maximal velocity, systolic (S’) and early diastolic maximal tissue Doppler velocity of mitral ring (E’), S’ measured at the lateral aspect of tricuspid ring and M-mode measurement of tricuspid annular plane systolic excursion (TAPSE), systolic pulmonary artery pressure, ratio of end-diastolic RV/LV areas

Interventions

DRUGDOBUTAMINE
DRUGsolution pour perfusion

Sponsors

Centre Hospitalier Et Universitaire De Limoges
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Evolution of a modified Sequential (Sepsis-Related) Organ Failure Assessment (SOFA) score (no gradation of the neurologic system) between baseline (before randomization) and Day 1, Day 2 and Day 3 after randomization.

Secondary

MeasureTime frame
Biological indices of tissue dysoxia at baseline, 6 h after initiating Dobutamine / placebo, Day 1, Day2, Day3: * Circulating lactate level as a marker of tissue hypoperfusion * Central venous oxygen saturation (ScvO2) as a marker of tissue oxygen extraction, Requirement of organ function supports during ICU stay: * Maximal dose and duration of open-labelled Dobutamine used as rescue therapy * Maximal dose and duration of vasopressor support (Norepinephrine, other) * Duration of invasive mechanical ventilation * Requirement and number of sessions of renal replacement therapy (excluding hemodialysis patient for chronic renal failure at the time of randomization, Hemodynamic status at baseline, 6 h after initiating Dobutamine / placebo, Day 1, Day2, Day3: * Arterial pressure, heart rate *Central venous pressure * Cardiac index and stroke volume measured using echocardiography or using calibrated monitoring systems (e.g., transpulmonary thermodilution), Severe cardiovascular adverse event

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026